Key Events This Week
8 June: Robust call option activity at ₹1,800 strike price signals bullish sentiment
9 June: Technical momentum shifts to bullish with mojo grade upgraded to Buy
10 June: Mixed technical signals emerge amid slight price dip
11 June: Surge in call option volume ahead of June expiry
12 June: Stock closes the week at ₹1,807.25, up 1.33%
8 June: Call Option Activity Signals Cautious Optimism
Sun Pharmaceutical emerged as the most actively traded stock in the call options segment on 8 June, with 6,364 contracts at the ₹1,800 strike expiring 30 June 2026. The turnover reached ₹773.35 lakhs, and open interest stood at 5,063 contracts. This activity indicated a cautiously bullish outlook, as the stock price closed at ₹1,788.60, up 0.28%, outperforming the Sensex which fell 1.33% that day.
Technically, the stock traded above its 50-, 100-, and 200-day moving averages, signalling medium- to long-term strength, though it remained below the 5- and 20-day averages, suggesting short-term consolidation. Delivery volumes had declined recently, reflecting some investor caution despite the positive price action.
9 June: Technical Momentum Shifts to Bullish with Mojo Upgrade
On 9 June, Sun Pharma’s mojo grade was upgraded from Hold to Buy, reflecting improved technical and fundamental outlooks. The stock closed slightly lower at ₹1,779.40 (-0.51%), but technical indicators showed strengthening momentum. The price remained comfortably above key moving averages, and weekly MACD signalled bullish momentum despite a mildly bearish monthly MACD.
RSI readings were neutral, while weekly Bollinger Bands suggested upward price pressure. The stock’s relative performance remained strong, with year-to-date gains of 4.00% versus the Sensex’s 13.72% decline. This upgrade and technical shift reinforced confidence in the stock’s medium-term prospects.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
10 June: Mixed Technical Signals Amid Slight Price Dip
The stock experienced a mild decline on 10 June, closing at ₹1,779.40 (-0.51%). Technical momentum shifted from bullish to mildly bullish, reflecting a moderation in buying pressure. Weekly MACD remained positive, but monthly MACD turned mildly bearish, signalling caution for longer-term investors.
RSI remained neutral, and Bollinger Bands suggested a sideways consolidation on the monthly chart, while weekly indicators showed mild bullishness. The stock’s relative performance continued to outpace the Sensex across multiple timeframes, underscoring its resilience despite short-term softness.
11 June: Surge in Call Option Volume Ahead of June Expiry
Call option activity surged again on 11 June, with 3,545 contracts traded at the ₹1,800 strike expiring 30 June 2026, generating a turnover of approximately ₹26.56 crores. Open interest increased to 5,970 contracts, signalling sustained bullish positioning despite the stock’s marginal underperformance that day, closing at ₹1,787.10 (+0.43%).
The stock remained above its key moving averages, though below the 20-day average, indicating short-term consolidation. Delivery volumes declined, but liquidity remained robust, supporting active options trading. The mojo score upgrade to 74.0 and Buy grade likely contributed to this bullish sentiment.
Sun Pharmaceutical Industries Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this large-cap stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth large-cap analysis
- - Valuation assessment included
12 June: Week Closes Strong with 0.72% Gain
Sun Pharmaceutical ended the week on a positive note, closing at ₹1,807.25, up 0.72% on 12 June. This final session’s gain contributed to the weekly rise of 1.33%, outperforming the Sensex’s 0.57% increase. The stock’s steady advance amid broader market volatility reflects sustained investor confidence and technical strength.
Volume was lower at 49,984 shares, but the stock maintained its position above key moving averages. The positive close capped a week marked by active options trading, technical upgrades, and relative outperformance within the Pharmaceuticals & Biotechnology sector.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-08 | Rs.1,788.60 | +0.28% | 34,673.90 | -1.33% |
| 2026-06-09 | Rs.1,779.40 | -0.51% | 34,979.26 | +0.88% |
| 2026-06-10 | Rs.1,787.10 | +0.43% | 34,766.59 | -0.61% |
| 2026-06-11 | Rs.1,794.30 | +0.40% | 34,580.95 | -0.53% |
| 2026-06-12 | Rs.1,807.25 | +0.72% | 35,342.50 | +2.20% |
Key Takeaways
Positive Signals: The week’s strong call option activity at the ₹1,800 strike price highlights bullish market positioning. The mojo score upgrade to Buy and technical momentum shifts underpin a positive medium-term outlook. Relative outperformance versus the Sensex across multiple timeframes confirms the stock’s resilience and sector leadership.
Cautionary Notes: Mixed technical signals, particularly the mildly bearish monthly MACD and KST indicators, suggest potential consolidation or volatility ahead. Declining delivery volumes indicate some investor hesitation, and short-term resistance near the 20-day moving average may temper immediate gains.
Conclusion
Sun Pharmaceutical Industries Ltd demonstrated a resilient and cautiously optimistic performance during the week ending 12 June 2026. The stock’s 1.33% gain outpaced the Sensex, supported by robust options market activity and a mojo grade upgrade to Buy. Technical indicators present a mixed but generally positive picture, with short-term momentum strengthening amid longer-term consolidation signals.
Investors should monitor upcoming price action closely, particularly around key moving averages and option expiry dates, to assess the sustainability of the current momentum. The company’s strong fundamentals, sector positioning, and improving technical outlook make it a noteworthy large-cap pharmaceutical stock to watch in the near term.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
